Agonist
Back to library
GLP-1Subcutaneous

Cagrilintide-Semaglutide (CagriSema)

Also known as: CagriSema · Cagrilintide + Semaglutide combo

Fixed-combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Combines satiety pathways from two independent receptor systems for additive weight loss beyond either monotherapy in Phase 2 trials.

At a glance

Half-life
6.9 days
Common route
Subcutaneous
Typical dose range
1,000–4,800mcg
Stability (reconstituted)
42days refrigerated

Best timing

Once weekly, both components administered together. Typically titrated in parallel — semaglutide on standard ramp, cagrilintide co-titrated.

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2
  • History of pancreatitis
  • Severe gastroparesis
  • Pregnancy

Watch symptoms

  • Nausea, vomiting (often more pronounced than semaglutide alone)
  • Decreased appetite to point of inadequate protein intake
  • Constipation
  • Injection site nodules from cagrilintide component
  • Mood flattening or anhedonia in some users

Citations

The primary literature.

  1. 01Semaglutide 2.4 mg plus cagrilintide 2.4 mg (CagriSema) in adults with overweight or obesityPubMed
  2. 02CagriSema once weekly in obesity (REDEFINE 1 trial program)PubMed
Back to library